Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02893579 · ClinicalTrials.gov registry record · NA

Stress Reduction Intervention for Women With Ischemic Heart Disease

A NA study, sponsored by NYU Langone Health.

Terminated
Registry status
NA
Development phase
6
Enrollment target

NCT02893579: Clinical Trial NA study, sponsored by NYU Langone Health.

NCT02893579 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02893579, a NA study, was terminated before completion, sponsored by NYU Langone Health.

TERMINATED
Registry status
NA
Development phase
6 participants
Enrollment target

Study Summary

This is a single center, randomized controlled trial which will include women with ischemic heart disease to receive either a self-directed stress reduction program delivered through a smart-phone application or activity tracking only for the first month ("early SR intervention" and "delayed SR intervention", respectively). Patients will be monitored for 1 month for application use and step counts via telephone or email interview and/or collection of screen-captured data. Baseline questionnaires will be repeated at the end of one month to assess for all primary and secondary measures, at which time the control group (activity tracking only) will be introduced to the intervention program. The early SR intervention group will not receive a new intervention but will be encouraged to continue using the app. Data will be collected for an additional 2 months with all participants in both groups. After the three-month study period, the study will close with the collection of final questionnaire data.

Primary Outcome

The Seattle Angina Questionnaire is a well-validated descriptive instrument for measuring quality of life across five dimensions of coronary artery disease: physical limitation, anginal stability, anginal frequency, treatment satisfaction and disease perception. 45 Patient SAQ scores have been found to be independently prognostic of subsequent mortality, hospitalization, and resource use.

Interventions

  • BEHAVIORAL Early SR intervention
  • BEHAVIORAL Delayed SR intervention

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2018-03-06
Est. Completion 2018-07-06
Phase NA
NYU Langone Health

1,164 total trials

Why NCT02893579 stopped before completion

NCT02893579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 2 interventions - of which Early SR intervention is the first listed.

NCT02893579 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02893579 about?

NCT02893579 is a clinical study titled "Stress Reduction Intervention for Women With Ischemic Heart Disease". This is a single center, randomized controlled trial which will include women with ischemic heart disease to receive either a self-directed stress reduction program delivered through a smart-phone application or activity tracking only for the first month ("early SR intervention" and "delayed SR inte...

What is the current status of trial NCT02893579?

This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2018-03-06. Estimated completion is 2018-07-06.

What interventions are being tested in trial NCT02893579?

The interventions under investigation include: Early SR intervention (BEHAVIORAL), Delayed SR intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02893579?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02893579's enrollment target sits among peer trials

6 1983rd of 2000 higher than 13 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02893579, the US trial registry maintained by the National Library of Medicine. NCT02893579 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.